; table of contents. Title I—ELIMINATING DELAYS OF GENERIC DRUGS AND BIOSIMILAR PRODUCTS Sec. 101. Actions for delays of generic drugs and biosimilar biological products. Sec. 102. REMS approval process for subsequent filers. Title II—INCREASING ACCESS TO DRUGS AND BIOSIMILAR PRODUCTS Sec. 201. Expedited development and priority review for generic complex drug products. Sec. 202. Increasing pharmaceutical options to treat an unmet medical need. Sec. 203. Preemption of State barriers to the substitution of biosimilar products. Sec. 204. Expedited process for biological products authorized for marketing in European Union. Title III—PRESCRIPTION DRUG PRICING AND COMPETITION Sec. 301. Medicare drug coverage. Sec. 302. Fee transparency between pharmacies and PBMs. Sec. 303. Sunset of limit on maximum rebate amount for single source drugs and innovator multiple source drugs. Sec. 304. Regulation of manufacturer-sponsored copay contributions. Title IV—PATENT DISCLOSURE REQUIREMENTS Sec. 401. Patent disclosure and transparency requirements. Sec. 402. Antitrust exemption for health insurance issuers to negotiate wholesale acquisition prices of prescription drugs purchased from drug manufacturers. Sec. 403. Fair treatment of Medicare part B billing codes for the prescribing of biosimilars. Title V—FIXING GLOBAL FREELOADING Sec. 501. Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative. I ELIMINATING DELAYS OF GENERIC DRUGS AND BIOSIMILAR PRODUCTS 101. Actions for delays of generic drugs and biosimilar biological products (a) Definitions In this section— (1) the term commercially reasonable, market-based terms means— (A) a nondiscriminatory price for the sale of the covered product at or below, but not greater than, the most recent wholesale acquisition cost for the drug, as defined in section 1847A(c)(6)(B) of the Social Security Act (42 U.S.C. 1395w–3a(c)(6)(B))